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Abstract
The Chemistry Department at the University of Nebraska – Lincoln (UNL) is located in Hamilton
Hall on the main campus of UNL in Lincoln, NE, USA. This department houses the primary
graduate and research program in chemistry in the state of Nebraska. This program includes the
traditional fields of analytical chemistry, biochemistry, inorganic chemistry, organic chemistry and
physical chemistry. However, this program also contains a great deal of multidisciplinary research
in fields that range from bioanalytical and biophysical chemistry to nanomaterials, energy
research, catalysis and computational chemistry. Current research in bioanalytical and biophysical
chemistry at UNL includes work with separation methods such as HPLC and CE, as well as with
techniques such as MS and LC–MS, NMR spectroscopy, electrochemical biosensors, scanning
probe microscopy and laser spectroscopy. This article will discuss several of these areas, with an
emphasis being placed on research in bioanalytical separations, binding assays and related fields.
High-performance affinity separations & chromatographic immunoassays
One area of active research at the University of Nebraska – Lincoln (UNL) is the
development of novel separations for biological and environmental samples based on high-
performance affinity chromatography (HPAC) and affinity CE (ACE). This work is carried
out in the laboratory of David S Hage. Both HPAC and ACE are based on the use of a
biologically related agent (e.g., an antibody, aptamer, receptor or transport protein) for the
selective recognition and binding of a target analyte in a sample [1–4]. In HPAC, the
selective binding agent is immobilized within a column and used as a stationary phase for
analyte retention [1,2,4]. In ACE, the binding agent is combined with the sample or placed
within the running buffer to bind to the target and alter its electrophoretic mobility, thereby
leading to the separation of this target from other sample components [3]. The selective,
strong interactions present in many biological systems help to make HPAC and ACE
powerful methods for the rapid study of specific targets in complex samples. These methods
can be used alone for the detection and measurement of analytes, or can be combined with
other techniques to develop multidimensional schemes for separation and analysis (e.g., the
use of immunoaffinity columns with reversed-phase LC or as part of an LC–MS system) [1–
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4]. A large number of routine and custom-designed HPLC systems are available for such
work in the Hage laboratory and in the facilities within the Chemistry Department at UNL.
A variety of detection formats are possible with these HPLC systems, including absorbance,
fluorescence or MS and more specialized modes such as chemiluminescence or near-
infrared fluorescence. Several CE systems are also available for use in this research with
either absorbance or fluorescence detection.
A specific topic area of emphasis in the Hage laboratory is the use of antibodies and other
selective binding agents in HPLC systems to produce ‘chromatographic immunoassays’
[5,6]. It has been demonstrated in the past that these methods can be used for the rapid and
selective measurements of drugs, hormones, peptides, proteins and many other targets in
biological samples. These properties make chromatographic immunoassays appealing for
use in clinical testing, pharmaceutical analysis, biotechnology and environmental studies [5–
15]. When used in combination with methods such as reversed-phase LC or CE,
chromatographic immunoassays can also be adapted for the simultaneous analysis of several
compounds within a given class of chemicals [5–9].
One application of Hage’s work in this area has been the creation of an automated and
portable system for the determination of triazine herbicides in environmental samples [7,8].
This method combined the use of a small antibody column with a reversed-phase HPLC
column and absorbance detection. This approach has been used in both the laboratory and in
a portable device for field work. In work with the portable system, it was possible to provide
results at the site of a river or stream within 10 min of sample injection. This approach has
been used not only for triazine herbicides, such as atrazine, but has been adapted for use
with other environmental agents (e.g., chloroacetic acid herbicides such as 2,4-D) by
changing the type of antibody column used in the system [7–9].
Other chromatographic immunoassays that have been developed by the Hage laboratory
include techniques for measuring specific hormones, peptides, drugs and proteins in clinical
samples [10–15]. These methods have been shown in numerous studies to be precise, easy to
automate and to take only a small period of time to perform (i.e., typically only a few
minutes). In addition, Hage’s group has explored and developed many formats for use in
these methods. These formats range from competitive binding assays to sandwich
immunoassays, displacement immunoassays and one-site immunometric assays. As part of
these studies, the Hage group has also been active in working with chromatographic theory
and computer models to describe the response and behavior of these assays under various
operating conditions [6,9,10,15].
A recent application of chromatographic immunoassays has been the development of ultra-
fast immunoextraction and the use of this approach to measure the ‘free fraction’ of a drug
or hormone in a biological sample (Figure 1) [10–12,16]. Ultrafast immunoextraction is
based on the use of an affinity microcolumn with a small layer of antibodies that can bind
quickly and selectively to the desired target. When used to measure the free fraction of a
drug or hormone, this free fraction is extracted by the antibody column in a very short period
of time (80–120 ms), which makes it possible to isolate this fraction without disturbing the
fraction of the drug or hormone that is bound by other sample components. The results of
this approach have been found to give good correlation with reference methods such as
ultrafiltration. However, this information can be obtained with chromatographic
immunoassays in much less analysis time than is required by other methods, making it an
attractive approach for use in pharmacological studies and in clinical chemistry for
personalized medicine [10–12].
Hage et al. Page 2
Bioanalysis. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chiral separations & studies of biological interactions
Two other ways that HPAC and ACE can be used is for chiral separations or to study
biological interactions (e.g., protein–protein binding or protein–drug binding). This research
is of current interest for the high-throughput screening of drug candidates for a given protein
and for predicting the behavior of drugs and proteins in the body by using separation
systems as models for these biological systems [4,17–20].
One protein the Hage group has studied extensively with regard to chiral separations and
drug–protein binding is human serum albumin (HSA). HSA is the most abundant protein in
serum and plays an important role in delivering many types of drugs throughout the body.
The Hage group has shown that HSA can be immobilized within HPLC columns and used in
rapid chiral separations [21–24] or to study how this protein binds to various drugs,
hormones and other small solutes in serum [21–32]. Chemicals that have been examined
with these HSA columns include warfarin, thyroxine, tryptophan, ibuprofen, digitoxin,
clomiphene, tamoxifen, phenytoin and carbamazepine. In addition, the Hage group has
recently created columns that contained the serum protein α1-acid glycoprotein (AGP) in a
fully active form that can be used in chiral separations or binding studies (Figure 2) [33–36].
The group has also developed columns containing complex particles such as high-density
lipoprotein and low-density lipoprotein for the investigation of drug interactions with these
binding agents in serum [37,38].
As part of this work, the Hage group has developed several new approaches for examining
the biological interactions by HPAC or ACE. Examples of these methods are approaches for
the study of low-solubility drugs [28–30], site-selective studies of agents with multiple
binding sites on a protein [25,31] and techniques for examining the interactions of drugs or
solutes that have allosteric interactions on a protein [39]. A variety of methods for
examining the kinetics of drug–protein interactions have also been created for use with
HPAC [40–43], along with HPAC and ACE approaches for examining the interactions of
drugs with the soluble form of a protein [10–12,19,20,44]. These approaches have been used
with both native proteins and with modified proteins, as has recently been demonstrated in
studies using HSA that has undergone non-enzymatic glycation [45–47]. Related work that
has been associated with these efforts has involved the creation of affinity microcolumns,
which can be used in binding studies with small amounts of proteins that have been obtained
from individuals and that can be examined in detail by HPAC over the course of hundreds of
experiments [45–49].
LC MS, GC MS & related methods
Research facilities are also available in the Chemistry Department for work in LC–MS and
GC–MS within the Nebraska Center for Mass Spectrometry. The GC–MS system consists of
an Agilent 6890N instrument with an auto-injection system and a Waters GCT TOF-MS for
work with either electron ionization or chemical ionization. There are also LC–MS systems
that use ESI, including Waters Q-TOF Ultima and Synapt G2 Q-TOF systems and a Thermo
LCQ ion-trap mass spectrometer. Equipment for conducting MALDI-TOF-MS is also
available in the center.
The group of Liangcheng Du makes use of many of these facilities as part of their research.
The Du group is studying the molecular mechanisms by which a variety of organisms (e.g.,
bacteria, fungi and plants) make structurally complex and biologically active natural
products. The goal of this work is to use this knowledge to produce new products through
genetic engineering that will be beneficial to humans. A specific example of this work
concerns the mechanism of biosynthesis for fungal polyketides. Polyketides are probably the
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most significant group of natural products in terms of their importance to human medicine.
Most studies to date with these compounds have focused on polyketides from bacteria.
Although fungi produce numerous polyketides, their biosynthetic mechanism remains
largely unknown. The Du group has been studying mycotoxin fumonisins, which are
produced by a number of economically significant fungi such as the pathogenic fungus
Fusarium verticillioides, which is a widespread contaminant of corn and maize-derived food
and feeds. The ingestion of fumonisin-contaminated corn causes fatal diseases in livestock
and imposes a cancer risk to humans. By using HPLC, GC–MS and LC–MS, the Du group
has identified multiple biosynthetic intermediates from various fungal strains, along with
mutants that are generated by specifically changing the biosynthetic genes for fumonisins.
This research has helped to reveal the pathway for the biosynthesis of fumonisin [50–52].
In another project, Du has been studying the genetics and function of novel antifungal
natural products such as heat-stable antifungal factor (HSAF; i.e., dihydromaltophilin).
HSAF has been isolated from the biocontrol agent Lysobacter enzymogenes C3 [53]. This
compound is a potent inhibitor of a wide range of fungi. The goals of the Du group in this
area have been to develop novel antifungal drugs for humans and ‘green’ strategies for
fungal disease control in agriculture. HPLC, MS and NMR have been used to determine the
structure of HSAF, which has a unique macrocyclic lactam system that contains a tetra-mic
acid moiety and a 5,5,6-tricyclic skeleton [54]. Du has also determined the biosynthetic
genes for this compound and has identified several compounds that are produced by gene
disruption and gene-replacement mutants [55].
The use of LC–MS or separation methods in combination with MALDI-TOF-MS is also of
interest to the Hage group. For instance, the group is using binding studies based on HPAC
to provide information on the function of a biological molecule and its interactions with
other compounds, while MS is used to provide information on the structure of the
biomolecule [56–59]. As an example, the group has used methods based on quantitative
proteomics and MS to examine the structure of immobilized HSA on HPLC supports [57].
The general scheme that was used for this research is shown in Figure 3. In this process, the
immobilized HSA was digested with a proteolytic enzyme in the presence of normal water,
while a soluble form of the same protein was digested in 18O-enriched water. After the
digestion reactions were quenched, the soluble fractions of the digests were combined,
fractionated and analyzed using MALDI-TOF-MS. This approach made it possible to
identify the major immobilization sites for HSA and to determine how these immobilization
sites might affect the binding of drugs to this protein in its immobilized form. A similar
approach has been used to compare the modifications that occur on glycated HSA versus
normal HSA and to examine the relationship between these modifications and the changes in
drug–HSA interactions that can occur during diabetes [58,59].
Ion mobility MS
Another capability that has recently been added at UNL is the use of separations based on
gas-phase ion mobility (IM) in conjunction with MS. This technique is the subject of
research in the laboratory of Eric D Dodds. The equipment used for this work is a Waters
Synapt G2 HDMS IM-enabled Q-TOF hybrid mass spectrometer. This instrument offers the
high mass accuracy (error < 1 ppm) and high mass resolution (m/Δm > 40,000) of a state-of-
the-art Q-TOF, as well as the ability to carry out MS/MS by means of collision-induced
dissociation or electron transfer dissociation. The IM feature of the instrument further
provides for the separation and collisional cross-section measurement of analyte ions. IM is
well-suited for use with LC and TOF-MS because the timescale of an IM separation (10−3 s)
lies between those for typical LC runs (103 s) and TOF-MS (10−6 s). This means that IM can
be used with LC and TOF-MS to provide an additional dimension of separation without
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increasing analysis time. The trade-off in combining these methods is a reduced duty cycle
because ions must be gated to the IM device rather than continuously sampled as a beam by
the TOF-MS.
An IM separation of isomeric peptides is shown in Figure 4. The two peptides shown in this
example contain the same amino acids, and therefore have the same exact mass, but these
peptides have their amino acids arranged in mirror sequences (i.e., SDGRG and GRGDS).
This pair of reverse-sequence peptides has been previously studied via IM [60,61] and
provides a convenient benchmark for determining IM resolution. In this example, the two
peptides are nearly baseline resolved as their doubly protonated ions. Aside from the
separation of isomers, IM fractionates ions of different charge states into separate regions of
drift time versus m/z space. Similarly, biomolecules of different classes (e.g., lipids vs
carbohydrates) are known to occupy distinct regions of this space [62]. This feature can be
useful for targeting analytes of a particular class or charge state.
The unique capabilities of IM are being applied in the Dodds laboratory to address various
questions concerning biomolecular structure. One area of application that is being examined
is that of site-specific glycoproteomics. Among the many ways in which proteins are
modified, glycosylation is uniquely complex and involves many levels of organization.
Rather than being merely present or absent at a given site, glycosylation can lead to the
possibility of site heterogeneity (e.g., different glycans occupying the same site on different
copies of a protein), as well as structural isomerism within a given glycan composition. In
conjunction with other separation and MS techniques, IM is being applied to address these
complexities. A second field of study that is being considered is in the interrogation of
quaternary architecture in noncovalent protein assemblies. As most proteins function as
noncovalent complexes, an appreciation of subunit stoichiometry and complex topology is
essential for an understanding of structure–function relationships. Condensed-phase and gas-
phase chemical strategies, including IM, are being utilized to probe the structures of protein
complexes that are sampled directly from physiological-like aqueous solutions. The
objective of this work is to obtain information on subunit arrangement and interfaces in
these systems.
NMR methods for ligand affinity screens & metabolomics
Complementary work in bioanalysis that is occurring at UNL is in the field of NMR
spectroscopy and the use of this method to examine a variety of biological problems. NMR
methods are currently being developed and used in the laboratory of Robert Powers to
understand the structure, function and evolution of novel proteins and their corresponding
therapeutic utility [63–65]. NMR is being employed in this work as part of a functional
genomics effort to determine the structures of biomolecules, to investigate biomolecular and
small-molecule interactions, to screen for functional ligands and potential drugs, and to
monitor in vivo protein and drug activity.
These NMR studies are carried out using equipment in the Chemistry Department’s
Research Instrumentation Facility. This facility operates and maintains several NMR
spectrometers, including a 600-MHz Bruker AVANCE spectrometer, which is a five-
channel NMR system capable of working with both solids and liquids. This instrument has
triple-axis gradients, enabling sophisticated gradient experiments involving multiple nuclei,
full broadband capabilities and a variable temperature unit for performing high and low
temperature experiments. This instrument is also equipped with a range of probes for use
with liquids, including a TXI triple resonance 1H/13C/15N probe optimized for protein
experiments. A second NMR instrument that is available is a three-channel 500-MHz Bruker
DRX NMR spectrometer with a variable temperature unit that features a 5 mm 1H/13C/15N
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cryoprobe. This system excels at the direct detection of protons and as a platform for the
indirect detection of 13C or 15N through 2D experiments. The addition of a Bruker
BACS-120 sample changer to this instrument allows for the high-throughput screening of
ligand-affinity interactions and work in metabolomics.
One method being developed in the Powers laboratory is functional annotation screening
technology by NMR (FAST-NMR), as illustrated in Figure 5 [66,67]. This method combines
structural biology and NMR ligand-affinity screens with bioinformatics to generate a
functional hypothesis that is based on structural and sequence similarities in ligand-binding
sites. FAST-NMR is similar in concept to sequence and structure homology. However,
instead of relying on global similarities, a functional assignment is made by focusing on
evolutionary stable functional regions. FAST-NMR incorporates a multistep NMR ligand-
affinity screening technique [68] with a rapid approach to generate protein–ligand co-
structures [69] and a technique to measure dissociation constants from NMR screens [70],
along with Comparison of Protein Active Site Structures and Protein Function, Evolution,
Structure and Sequence as tools for bioinformatics [71,72]. Over 24 proteins have been
examined by this FAST-NMR assay. These proteins have included Staphylococcus aureus
protein SAV1430, Pseudomonas aeruginosa protein PA1324, Pyrococcus horikoshii OT3
protein PH1320, human protein Q13206, Bacillus subtilis protein YndB and Salmonella
typhimurium PrgI protein [66,67,73,74]. Recent efforts with this approach have focused on
the analysis of proteins of unknown function that are associated with pancreatic cancer.
NMR spectroscopy has also been used for differential metabolomics by the Powers group
[75–78]. In this work, NMR is used to examine the metabolome of lyzed cells or body fluids
and to study changes that result from the influence of disease, drug treatments or
environmental stress. NMR combined with principal component analysis is used to measure
global changes between cells under various conditions. Similarly, NMR combined with 13C-
labeled metabolites permits a detailed analysis of metabolite concentration changes. This
differential NMR metabolomics methodology is currently being used to understand the
biofilm of staphylococcus, to understand mechanisms of drug activity and resistance in
tuberculosis, to identify biomarkers for multiple sclerosis, to improve the industrial-scale
production of diphtheria toxin and to aid in drug discovery for pancreatic cancer.
Development of new supports & separation media for bioanalysis
One unique capability of researchers in the Chemistry Department at UNL is their ability to
create, characterize and evaluate a variety of novel materials for use in separation methods.
For instance, Hage has been active for many years in the optimization and creation of new
schemes for immobilizing and modifying biological agents for use in HPAC or other
bioanalytical methods [16,23,24,33,37,79–85]. Facilities in Hage’s group can be used with
both covalent and noncovalent immobilization methods to place proteins, drugs, nucleic
acids or other agents on inorganic materials, organic polymers or carbohydrate-based
materials (e.g., silica or glass, methacrylate or agarose). As one example, Hage’s group has
developed a method that can be used for the site-selective immobilization of antibodies to
silica through their carbohydrate chains [79]. The same group has optimized techniques for
immobilization of the proteins HSA, α1-acid glycoprotein and high-density lipoprotein, and
has recently reported a noncovalent entrapment method for protein and ligand
immobilization that can be used with silica or other porous HPLC supports [21,23,24,33–
35,37,80,82,83,85]. A variety of tools have been used in the creation and optimization of
these immobilization methods. These tools have included protein assays, infrared
spectroscopy, solid-state NMR spectroscopy and MS, as well as HPLC and CE [57,79–
81,83–87].
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Along with new methods for preparing stationary phases, additional work is being
conducted in the Hage group for the creation of improved support materials for HPLC and
related methods. A set of supports that are of current interest are monolithic materials
[88,89]. Monolith columns consist of a continuous bed of a porous material that contains a
stationary phase, but also allows flow of a mobile phase through the bed. Monolith columns
are of great interest in HPLC because of their good mass transfer properties and low back
pressures, allowing these materials to provide efficient separations at high-flow rates. The
Hage group has been developing affinity monolith supports for use with antibodies, proteins
and other binding agents [88,89]. These studies have included monoliths based on organic
copolymers (e.g., glycidyl methacrylate and ethylene dimethacrylate) and silica monoliths
(Figure 6). These materials have been used in applications that include ultra-fast
immunoextraction, HPAC assays for pharmaceutical agents, chiral separations and studies
of drug–protein binding [16,23,24,35,49].
The Center for Nanohybrid Functional Materials has recently been created at UNL to further
investigate and create novel materials for use in applications such as HPLC, biosensing and
bioanalytical separations. This center consists of 15 faculty members from UNL, the
University of Nebraska Medical Center, the University of Nebraska – Kearney, Creighton
University (NE, USA) and Doane College (NE, USA). The goal of this center is to create,
test and utilize new materials that consist of ordered nanostructural scaffolds that are
functionalized or hybridized with chemical and biological recognition elements. These
nanoscaffolds are being prepared with control of 3D morphology and with a variety of
frameworks, one set of which includes an expanded set of supports for monolithic columns.
As these scaffolds are developed they will be combined with binding agents such as
antibodies or aptamers for use in flow-based biosensors or bioanalytical separations.
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Executive summary
• Research efforts in the field of bioanalysis and separations at the Chemistry
Department of University of Nebraska – Lincoln (UNL) include work with
HPLC, CE, MS, NMR spectroscopy and several other techniques.
• One area of active research at UNL is in the development of novel separation
methods based on high-performance affinity chromatography and affinity CE,
such as the use of antibodies in HPLC systems to create chromatographic
immunoassays or multidimensional separation methods.
• The use of separation systems such as high-performance affinity
chromatography or affinity CE for the study of biological interactions and for
chiral separations is another field of ongoing research at UNL. This work is of
interest for the creation of new methods for the high-throughput screening of
drug candidates or for predicting and modeling the behavior of drugs and
proteins in the body.
• The techniques of LC–MS, GC–MS and NMR are being used to discover new
natural products and to study their biosynthetic mechanisms. In addition, affinity
separations are being used with MS and LC–MS to study and relate the effects
of protein modifications with changes in protein function.
• Gas-phase ion mobility is being used for the gas-phase separation of isomeric
biomolecules. This method is also being explored as a means for sorting
different classes of biomolecules according to their masses, charges and
collisional cross-sections.
• The combined use of structural, biological and NMR ligand-affinity screens
with bioinformatics is being used to generate functional assignments for
proteins. NMR spectroscopy is also being used for studies in metabolomics.
• Several efforts are underway at UNL regarding the creation of new supports and
separation media for bioanalysis. Two examples are the generation of improved
immobilization methods for use with biomolecules and the development of
monolith materials for use in high-performance affinity separations. A new
center aimed at the creation of nanohybrid functional materials has also been
created at UNL.
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Figure 1. (A) General design of a small affinity column for use in ultrafast immunoextraction
and (B) the extraction of fluorescein as a model target by immobilized antibodies within such a
column
The plot in (B) indicates that 95% extraction of the target could be obtained in 100 ms by
this approach. The components in (A) were as follows: (1) connection tubing, (2) fitting, (3)
end fitting assembly, (4) column casing, (5) frit, (6) sample distributor, and (7) affinity
column or affinity disk.
Adapted with permission from [16].
Hage et al. Page 14
Bioanalysis. Author manuscript; available in PMC 2012 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. General structure of a silica support containing immobilized α1-acid glycoprotein, and
the use of this support in the chiral separation of (R)- and (S)-propranolol
The conditions used in this separation were as follows: mobile phase: pH 7.4; 0.067 M
phosphate buffer with 2% (v/v) 2-propanol; temperature: 37°C; flow-rate: 2.00 ml/min.
Adapted with permission from [34].
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Figure 3. (A) The use of 18O/16O-labeling with quantitative proteomics and MS to examine the
immobilization sites for a protein on a solid support and (B) the results that were obtained with
this approach for human serum albumin that was immobilized to HPLC-grade silica by the
Schiff base method
The results for human serum albumin show the most common residues found to be involved
in the covalent immobilization of this protein. These results also show the locations of these
residues when compared with the two main sites for drug interactions with human serum
albumin (i.e., Sudlow sites I and II).
Adapted with permission from [57].
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Figure 4. Ion mobility separation of the reverse sequence peptides SDGRG and GRGDS
The [M+2H]2+ ions are observed at m/z 246.1 (monoisotopic).
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Figure 5. Flow chart for a functional annotation screening technology-NMR assay
Functionally uncharacterized proteins are first screened against mixtures of ligands from the
functional chemical library. Reference 1D 1H NMR spectra of the mixtures are then
compared with those containing the protein, where a hit is identified by changes in NMR
line width. Only the ligands identified as binding in the primary screen are further assayed in
the secondary 2D 1H–15N HSQC NMR experiment. Chemical shift changes are used to
confirm a specific interaction and to identify the binding site from mapping of the chemical
shift perturbations on the protein’s surface. The binding site and chemical shift perturbations
are utilized to determine a rapid co-structure using AutoDock. This co-structure is then used
by the CPASS to compare the ligand-defined binding site from the hypothetical protein to
all other protein–ligand interactions present in the protein database. A general biological
function can then be assigned based on an observed similarity to a ligand-defined binding
site for a protein of known function.
CPASS: Comparison of Protein Active Site Structures.
Reproduced with permission from [67].
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Figure 6. Effect of changing the relative amount of dodecanol in the porogen during monolith
preparation on the amount of immobilized IgG-class antibodies that could be attached to
poly(glycidyl methacrylate-co-ethylene dimethacrylate) (GMA/EDMA) monoliths
The star in the top diagram shows the conditions under which the maximum amount of
immobilized IgG was obtained.
DoOH: Dodecanol.
Adapted with permission from [16].
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